Nectar Lifesciences announced the sale of its active pharmaceutical ingredients (API) and formulations business to Ceph Lifesciences for ₹1,270 crore, along with the sale of assets related to its menthol business for ₹20 crore. An extraordinary general meeting (EGM) is scheduled for August 4, 2025, to approve the sale and appoint new management. Following the announcement, Nectar Lifesciences shares dropped 15%, hitting a 52-week low amid investor sell-off. Meanwhile, Pharmer Research has withdrawn its earlier decision to proceed with a corporate spin-off. In Japan, Kobayashi Pharmaceutical declared its exit from direct-to-consumer sales via its own e-commerce site and call center as part of its structural reforms. The company will continue sales through third-party channels. This move follows the suspension of its mid-term management plan earlier in the year due to health concerns linked to some dietary supplements, prompting efforts to streamline operations and improve corporate governance.